Stop press - Pfizer and Ranbaxy Settle Lipitor dispute (mostly) Worldwide
Duncan Bucknell’s site updates: Well it looks as though all good things, including IP Scorecards must come to an end. Pfizer and Ranbaxy have decided to (mostly) settle the global lipitor patent battle. The Lipitor Scorecard has been updated, so go and have a look at the latest results - across 23 countries.
For those keen on a little pharmaceutical patent blood sport, don’t despair, the battle wages on in five European counries: Finland, Spain, Portugal, Denmark and Romania
Here’s the press release from Pfizer:
Pfizer and Ranbaxy Settle Lipitor Patent Litigation (mostly) Worldwide
Ranbaxy to Receive License in U.S. on November 30, 2011;
NEW YORK–(BUSINESS WIRE)–Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world’s most-prescribed cholesterol-lowering medicine. Under the terms of the agreement, Ranbaxy will have a…